Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline

RIDGEFIELD, Conn., June 6 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced its pipeline of oral antidiabetic compounds, establishing itself in the type 2 diabetes therapeutic area. The Company is investigating compounds in Phase II and Phase III clinical development worldwide. New Phase II data results for linagliptin (BI 1356), a dipeptidyl peptidase 4 (DPP-4) inhibitor and the Company's lead diabetes compound, were presented today at the 69th Annual American Diabetes Association (ADA) Scientific Sessions in New Orleans.

"Type 2 diabetes is a growing public health concern," said J. Martin Carroll, Boehringer Ingelheim USA Corporation president and CEO. "Our Company will draw from its knowledge and experience to help us deliver on the much needed treatment options for patients who are living with the disease. Boehringer Ingelheim is inspired to make a difference in diabetes care."

Results from the Phase II study presented at ADA show that 1, 5 and 10 mg doses of linagliptin achieved clinically relevant and statistically significant reductions in HbA1c, a measure of blood sugar, when given as add-on therapy to type 2 diabetes patients inadequately controlled on metformin (placebo-corrected changes from baseline; -0.40 percent for the 1 mg dose, -0.73 percent for the 5 mg dose, and -0.67 percent for the 10 mg dose).(1) The most frequently reported adverse events in patients treated with all doses of linagliptin compared to placebo were nasopharyngitis, (7.1 vs. 9.9 percent) diarrhea (2.5 vs. 4.2 percent) and nausea (3.5 vs. 4.2 percent). No cases of hypoglycemia were reported in patients receiving linagliptin.(1)

"Many patients don't achieve adequate blood sugar control with commonly used diabetes medications like metformin. The significant reduction in HbA1c levels seen in this trial is encouraging as it indicates linagliptin may have a potential role in the management of this prevalent disease," said Dr. Thor Voigt, senior vice president, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "Type 2 diabetes is a progressive chronic condition that frequently requires long-term treatment. A range of treatment options and combination regimens are needed so physicians can tailor therapy to the individual patient needs. We are now awaiting results from additional ongoing studies which will further assess the full potential of linagliptin for the treatment of type 2 diabetes."

DPP-4 inhibitors are a newer class of oral hypoglycemics that target the incretin hormones GLP-1 and GIP, which are believed to be involved with regulating blood sugar.(2)

Linagliptin is a compound discovered by Boehringer Ingelheim and is being developed as an oral once-daily tablet for the treatment of type 2 diabetes. The compound is currently being studied in five pivotal Phase III clinical trials including more than 4,000 patients. These trials are fully recruited and underway globally and in many states across the U.S.(3)

Boehringer Ingelheim is also investigating sodium-dependent glucose co-transporter-2 inhibitors (SGLT-2 inhibitors), which are a new, emerging class of antidiabetic compounds that block tubular reabsorption of glucose in the kidney.(4) Phase IIb clinical trials for this innovative approach to diabetes treatment are underway. There are currently no SGLT-2 inhibitors approved by the U.S. Food and Drug Administration (FDA).

About the linagliptin (BI 1356) Phase II study

The aim of the 12-week, international, randomized, double-blind placebo-controlled study was to assess the efficacy and safety profile of linagliptin as add-on therapy in patients with type 2 diabetes who were failing to achieve glycemic control despite being treated with metformin.(1) The primary endpoint was the change in HbA1c from baseline to week 12.(1) Out of the 333 randomized patients, 268 patients received double-blind treatment with linagliptin (1 mg, n=65; 5 mg, n=66; 10 mg, n=66) or placebo.(1) An open-label arm with 65 patients on glimepiride was added for descriptive control.(1)

Additional results from the study

The addition of linagliptin to metformin treatment for 12 weeks resulted in clinically relevant and statistically significant reductions in HbA1c and fasting blood sugar or fasting plasma glucose (FPG) levels (p-values of less than 0.05%):(1)

  • Statistically significant reductions in mean HbA1c levels with linagliptin 5 mg and 10 mg compared with metformin alone (both p<0.001) were observed from week four though week 12.(1)
  • In addition, all linagliptin doses showed significant reductions in FPG levels compared with metformin alone (placebo-corrected mean changes from baseline; -19.2 mg/dL for 1 mg, -34.7 mg/dL for 5 mg, and -29.0 mg/dL for 10 mg).(1)
  • In the open-label comparator arm, the placebo-corrected mean change from baseline in HbA1c was -0.90 percent.(1)
  • More than 85% of the patients receiving the 5mg and 10mg doses of linagliptin demonstrated greater that or equal to 80% DPP-4 inhibition at trough at week 12(1)
  • HbA1c reductions of at least 0.5 percent were achieved in 44 percent to 53 percent of patients on linagliptin, but only in 13 percent of the patients receiving metformin alone.(1)

About type 2 diabetes

There are approximately 23.6(5) million Americans and 246 million people worldwide(6) with diabetes. Type 2 diabetes is the most common type of diabetes accounting for more than 90% of all diabetes cases in the developed world.(7) Every ten seconds two people develop diabetes and one person dies from diabetes-related causes around the world.(6) Each year, more than 200,000 people in North America(6) and more than 3.8 million people worldwide die from diabetes and its complications(6) -- a number which is expected to increase by more than 50 percent over the next decade.(7) Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone, insulin.(6)

To address this unmet need, Boehringer Ingelheim is committed to researching and developing new compounds in this therapeutic area.

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit

(1) DPP-4 inhibitor linagliptin improves glycaemic control in type 2 diabetes patients when added to onogoing metformin therapy. ADA, 05-09 June 2009, New Orleans, U.S.A.

(2) Nathan DM et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. Diabetes Care 21:1-11, 2008.

(3) Available at: Accessed on: April 30, 2009.

(4) Jabbour SA, et al. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. International Journal of Clinical Practice, July 2008. 62, 8, 1279-1284.

(5) American Diabetes Association. 2007 National Diabetes Fact Sheet.

(6) International Diabetes Federation. Diabetes Atlas. 3rd edn. Brussels: International Diabetes Federation, 2006.

(7) World Health Organization. Fact Sheet No. 312: What is Diabetes? Available at: Accessed on: February 4, 2009.

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
(Date:1/21/2017)... -- According to a new market research report "Life ... SCM), Component (Software, Service), Delivery (On premise, Cloud), End user (Pharmaceutical, ... the market is expected to reach USD 24.73 Billion by 2021 ... during the forecast period. Continue Reading ... ...
(Date:1/21/2017)... Jan 20, 2017 Research and Markets has ... & Trends - Technology, Route Of Administration, End User - Forecast ... ... poised to grow at a CAGR of around 7.8% over the ... This industry report analyzes the global markets for Advanced Drug ...
(Date:1/20/2017)... 2017 Research and Markets has announced ... Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales Volume, Company ... ... Hearing Aids Market Sales Volume, Company Analysis and Forecast to ... aid industry. The growing prevalence of hearing impairment ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud ... Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This ... 2008 to address the limitations of fatigue monitoring technologies within the mining industry. ...
(Date:1/23/2017)... ... January 23, 2017 , ... The American Academy of ... scientific development, healthcare training and clinical application of medical infrared imaging, has announced ... Certification Qualification Courses for Technicians, respectively. , For the first time the AAT ...
(Date:1/23/2017)... ... January 23, 2017 , ... "ProRandom is a set of camera tools that allow video editors ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... text with video footage. ProRandom works by using a virtual camera to create the ...
(Date:1/23/2017)... ... ... “Crossing the Bar”: a moving and eloquent drama depicting the events that happen ... creation of published author, Charlotte Hotte, a North Carolina native, a mother of two, ... book to her sister, Denise, wishes to acknowledge her savior, Jesus Christ, along with ...
(Date:1/22/2017)... (PRWEB) , ... January 22, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired by the ... key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, ...
Breaking Medicine News(10 mins):